Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on February 12, 2015. The report discloses corporate governance actions regarding executive compensation, specifically the approval of 2015 base salaries and 2014 performance bonuses for Named Executive Officers (NEOs).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
| Named Executive Officer | 2015 Base Salary | 2014 Bonus Payment |
|---|---|---|
| Richard A. King, CEO | $490,000 | $91,875 |
| Timothy E. Morris, CFO | $386,500 | $70,137 |
| Pamela P. Palmer, CMO | $438,000 | $104,987 |
| Badri Dasu, Chief Engineering Officer | $321,000 | $67,867 |
| Lawrence G. Hamel, Chief Development Officer | $321,000 | $65,695 |
Material Changes
The Board of Directors approved 2015 base salaries effective retroactively to January 1, 2015. Additionally, bonus payments for 2014 performance were approved in accordance with the Company's established 2014 Cash Bonus Plan. The filing text does not provide prior year salary data to quantify percentage changes.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, risk factors, or discussion of contingencies. The document is limited to the disclosure of compensatory arrangements for certain officers.
Investor Verification Checklist
- Verify the total cash compensation impact on the company's operating expenses for the 2015 fiscal year.
- Confirm the performance metrics used to calculate the 2014 bonuses under the Cash Bonus Plan.
- Review the company's most recent 10-K or 10-Q for broader financial health indicators not present in this 8-K.
- Note the discrepancy between the request metadata (TALPHERA, INC.) and the filing content (ACELRX PHARMACEUTICALS, INC.).